Lentiviral Transduction of Mammalian Cells

Protocol boundary

Use this as general guidance

Cell-line-specific instructions, assay kit documentation, institutional biosafety requirements, and your lab's validated SOP should take priority when they differ from this general workflow.

Materials

Materials and reagents

Protocol

Step 1: Prepare Lentiviral Particles

Lentiviral vector particles are commonly produced using HEK293T-derived packaging cells.

Healthy packaging cells are co-transfected with a transfer construct and the required packaging and envelope components according to the validated vector system.

After transfection, allow the packaging cells to produce vector particles. Lentivirus-containing culture supernatant is commonly collected approximately 48–72 hours after transfection. This time window is widely used in published lentiviral-vector workflows. (PubMed Central (PMC))

Remove cellular debris from the harvested supernatant using the approved clarification procedure.

For applications requiring higher functional titers, vector preparations may be concentrated using a validated laboratory method. Avoid repeated freeze-thaw cycles because these can reduce functional vector activity.

Protocol

Step 2: Titrate Virus

Determine functional vector titer before attempting quantitative transduction experiments.

Without titration, the amount of active vector delivered to target cells is unknown and results may vary substantially between preparations.

A common strategy is to prepare serial dilutions of the vector stock and expose a defined number of permissive cells to each dilution.

Functional titer can then be estimated using:

• Flow cytometry when the vector expresses a fluorescent marker
• Antibiotic-resistant colony formation
• qPCR-based vector measurements
• Other validated functional assays
• Flow-cytometric measurements are commonly performed approximately 48–72 hours after transduction for fluorescent reporters. (PubMed Central (PMC))

Titer information allows calculation of the approximate multiplicity of infection (MOI), or the number of functional vector particles applied per target cell.

Protocol

Step 3: Transduce Target Cells

Seed healthy target cells at an appropriate density before transduction.

Add the lentiviral vector preparation at a selected MOI. An MOI of approximately 1–10 is a practical optimization range for many research cell lines, but susceptibility varies widely.

A low MOI may provide insufficient gene delivery, whereas unnecessarily high vector exposure can increase toxicity, copy number, or other undesired effects.

Polycationic transduction enhancers such as hexadimethrine bromide or protamine sulfate can improve vector interaction with cells by reducing charge-related barriers. However, these agents can be toxic to sensitive cell types and should be titrated independently. Published workflows commonly use hexadimethrine bromide around 8–10 µg/mL, illustrating the need for cell-specific optimization. (PubMed Central (PMC))

Following an appropriate exposure period, replace the vector-containing medium with fresh complete culture medium according to the validated protocol.

Protocol

Step 4: Select and Expand Transduced Cells

If the vector contains an antibiotic-resistance marker, begin selection after cells have had sufficient time to express the resistance gene.

Common selection agents include puromycin, blasticidin, and G418.

Puromycin concentrations around 1–2 µg/mL are effective for some commonly used mammalian cell lines, but sensitivity varies dramatically. A kill curve using untransduced cells should therefore be performed before selection. Published protocols demonstrate effective puromycin concentrations in this approximate range for some cell systems while explicitly recommending cell-specific kill curves. (PubMed Central (PMC))

Continue selection until the untransduced control population is eliminated.

Expand the surviving population and confirm transgene delivery by an appropriate method such as fluorescence, qPCR, Western blotting, or functional analysis.

Protocol

Expected Results

A successful transduction should produce a measurable transgene-positive population after approximately 48–72 hours.

Following antibiotic selection, the surviving population should be substantially enriched for cells carrying the resistance construct.

Stable populations should maintain the expected phenotype during subsequent expansion, although expression level may vary among individual cells.

Troubleshooting

Common problems to check

Low Transduction Efficiency

Confirm functional vector titer, target-cell health, MOI, and the compatibility of the selected transduction enhancer.

High Cell Toxicity

Reduce MOI or enhancer concentration and evaluate whether toxicity originates from the vector preparation, enhancer, or selection conditions.

All Cells Die During Selection

The antibiotic concentration may be excessive or resistance-gene expression may not have developed sufficiently before selection.

Untransduced Cells Survive

Selection pressure may be too low. Establish the minimum effective concentration with a kill curve rather than increasing antibiotic concentration arbitrarily.

Products

Related products

Related knowledge

Continue learning